Dead Space in Mechanical Ventilation With Constant Expiratory Flow

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversity Hospital, Antwerp

About this trial

Conventional continuous mandatory mechanical ventilation relies on the passive recoil of the chest wall for expiration. This results in an exponentially decreasing expiratory flow.

Flow controlled ventilation (FCV), a new ventilation mode with constant, continuous, controlled expiratory flow, has recently become clinically available and is increasingly being adopted for complex mechanical ventilation during surgery.

In both clinical and pre-clinical settings, an improvement in ventilation (CO2 clearance) has been observed during FCV compared to conventional ventilation. Recently, Schranc et al. compared flow-controlled ventilation with pressure-regulated volume control in both double lung ventilation and one-lung ventilation in pigs. They report differences in dead space ventilation that may explain the improved CO2 clearance, although their study was not designed to compare dead space ventilation within the group of double lung ventilation.

Dead space ventilation, or "wasted ventilation", is the ventilation of hypoperfused lung zones, and is clinically relevant, as it is a strong predictor of mortality in patients with the acute respiratory distress syndrome (ARDS) and is correlated with higher airway driving pressures which are thought to be injurious to the lung (lung stress).

This trial aims to study the difference in dead space ventilation between conventional mechanical ventilation in volume-controlled mode and flow controlled-ventilation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults [18-70] yrs

General anaesthesia for elective surgery

Arterial line, central venous line and endotracheal tube as part of standard of care

Expected duration of controlled mechanical ventilation ≥ 60 minutes

Disqualifiers

One lung ventilation

Known pregnancy

Increased intra-abdominal pressure (pneumoperitoneum or obesity (BMI > 30kg/m2))

COPD GOLD IV or home oxygen dependence

Trial design

Design model

Crossover

Treatments tested in this trial

  • Flow-controlled ventilation (FCV)

    Device

    20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)

  • Conventional volume-controlled ventilation (VCV)

    Device

    20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.

Treatment groups

13 Participants
are divided into 2 treatment groups
Group A: FCV-VCVExperimental treatment 2 interventions
Group B: VCV-FCVExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Change in Bohr dead space ventilation (VDBr/VT)

Quantified by the Bohr approach with volumetric capnography

Time frame
During FCV and VCV measurements (20 minutes)

Secondary outcomes

1

Change in Enghoff dead space ventilation (VDEng/VT)

Quantified by the Enghoff approach with volumetric capnography

Time frame
During FCV and VCV measurements (20 minutes)
2

Change in physiological dead space volume (Vdfys)

Measured with volumetric capnography and Enghoff's approach

Time frame
During FCV and VCV measurements (20 minutes)
3

Change in airway dead space volume (Vdaw)

Measured with volumetric capnography and Fletcher's approach

Time frame
During FCV and VCV measurements (20 minutes)
4

Change in alveolar dead space volume (Vdalv)

As measured with volumetric capnography and Fletcher's approach

Time frame
During FCV and VCV measurements (20 minutes)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Antwerp

Lead sponsor

Universiteit Antwerpen

Collaborator